<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189436</url>
  </required_header>
  <id_info>
    <org_study_id>BUD ER 3425</org_study_id>
    <secondary_id>RC - 3425</secondary_id>
    <nct_id>NCT00189436</nct_id>
  </id_info>
  <brief_title>Effect of Nebulized Budesonide and Oral Corticosteroids on Wheezing Episode Relapse in Children</brief_title>
  <acronym>BudER</acronym>
  <official_title>A Pilot Study to Evaluate the Effect of Nebulized Budesonide and Oral Corticosteroids on Wheezing Episode Relapse in Pediatric Patients Following Discharge From the Emergency Department/Outpatient Care Facility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West Penn Allegheny Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>West Penn Allegheny Health System</source>
  <brief_summary>
    <textblock>
      Subjects aged 1-8 years who have been discharged from the emergency department/outpatient
      care facility with a diagnosis of asthma/bronchospasm/wheezing after usual standard care will
      be enrolled into this open-label, randomized, parallel-group study to compare the efficacy of
      nebulized budesonide and oral corticosteroids in preventing asthma exacerbation relapse rates
      during the 21-day follow-up period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary outcomes include urinary cortisol-creatinine rations, symptom severity scores and
      peak flow rates.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wheezing/Asthma/Bronchospasm Relapse Rate</measure>
    <time_frame>3 weeks</time_frame>
    <description>Asthma relapse rate was 6.5% and 4% in the nebulized budesonide and standard care groups, respectively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary Cortisol</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometry Readings</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Treatment with Budesonide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject is treated with nebulized budesonide 0.5 BID for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject is treated with usual care as provided by the doctor. Usual care normally consists of treatment with albuterol with or without an oral steroid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulized Budesonide</intervention_name>
    <description>Subject is treated with nebulized budesonide 0.5 BID for 3 weeks</description>
    <arm_group_label>Treatment with Budesonide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Usual care (albuterol with or without oral steroid)</intervention_name>
    <description>Subject is treated with usual care as prescribed by the doctor (normally albuterol with or without oral steroid)</description>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children ages 1-8 years old

          -  Discharge from emergency department/outpatient clinic with a diagnosis of asthma
             exacerbation after usual standard care

          -  Subjects must be able to show efficient use with a jet nebulizer

        Exclusion Criteria:

          -  Subjects requiring hospitalization

          -  Subjects receiving oral steroids 1 week prior to presentation to emergency department.

          -  Subjects with FEV1 &lt; 50% of predicted

          -  Subjects with co-morbid medical conditions (renal or cardiovascular disease)

          -  Subjects with reported history of HIV

          -  Subjects unable to follow up for study visits

          -  Subjects who are frequently enuretic
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Skoner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Penn Allegheny Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bellevue Pediatric Associates</name>
      <address>
        <city>Bellevue</city>
        <state>Pennsylvania</state>
        <zip>15202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <results_first_submitted>July 8, 2014</results_first_submitted>
  <results_first_submitted_qc>July 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2014</results_first_posted>
  <last_update_submitted>July 8, 2014</last_update_submitted>
  <last_update_submitted_qc>July 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West Penn Allegheny Health System</investigator_affiliation>
    <investigator_full_name>David Skoner, MD</investigator_full_name>
    <investigator_title>Director, Allergy and Asthma Institute</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Sounds</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment With Budesonide</title>
          <description>Subject is treated with nebulized budesonide 0.5 BID for 3 weeks
Nebulized Budesonide: Subject is treated with nebulized budesonide 0.5 BID for 3 weeks</description>
        </group>
        <group group_id="P2">
          <title>Usual Care</title>
          <description>Subject is treated with usual care as provided by the doctor. Usual care normally consists of treatment with albuterol with or without an oral steroid.
Usual care (albuterol with or without oral steroid): Subject is treated with usual care as prescribed by the doctor (normally albuterol with or without oral steroid)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>61 subjects were enrolled and 31 were randomized to nebulized budesonide and 30 to standard of care. 74% of subjects enrolled in the nebulized budesonide and 83% enrolled in the standard care group completed the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment With Budesonide</title>
          <description>Subject is treated with nebulized budesonide 0.5 BID for 3 weeks
Nebulized Budesonide: Subject is treated with nebulized budesonide 0.5 BID for 3 weeks</description>
        </group>
        <group group_id="B2">
          <title>Usual Care</title>
          <description>Subject is treated with usual care as provided by the doctor. Usual care normally consists of treatment with albuterol with or without an oral steroid.
Usual care (albuterol with or without oral steroid): Subject is treated with usual care as prescribed by the doctor (normally albuterol with or without oral steroid)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.8" spread="2.0"/>
                    <measurement group_id="B2" value="5.4" spread="1.6"/>
                    <measurement group_id="B3" value="5.1" spread="0.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Wheezing/Asthma/Bronchospasm Relapse Rate</title>
        <description>Asthma relapse rate was 6.5% and 4% in the nebulized budesonide and standard care groups, respectively</description>
        <time_frame>3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment With Budesonide</title>
            <description>Subject is treated with nebulized budesonide 0.5 BID for 3 weeks
Nebulized Budesonide: Subject is treated with nebulized budesonide 0.5 BID for 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Subject is treated with usual care as provided by the doctor. Usual care normally consists of treatment with albuterol with or without an oral steroid.
Usual care (albuterol with or without oral steroid): Subject is treated with usual care as prescribed by the doctor (normally albuterol with or without oral steroid)</description>
          </group>
        </group_list>
        <measure>
          <title>Wheezing/Asthma/Bronchospasm Relapse Rate</title>
          <description>Asthma relapse rate was 6.5% and 4% in the nebulized budesonide and standard care groups, respectively</description>
          <units>percentage of cases of asthma relapse</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5"/>
                    <measurement group_id="O2" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Cortisol</title>
        <time_frame>3 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spirometry Readings</title>
        <time_frame>3 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment With Budesonide</title>
          <description>Subject is treated with nebulized budesonide 0.5 BID for 3 weeks
Nebulized Budesonide: Subject is treated with nebulized budesonide 0.5 BID for 3 weeks</description>
        </group>
        <group group_id="E2">
          <title>Usual Care</title>
          <description>Subject is treated with usual care as provided by the doctor. Usual care normally consists of treatment with albuterol with or without an oral steroid.
Usual care (albuterol with or without oral steroid): Subject is treated with usual care as prescribed by the doctor (normally albuterol with or without oral steroid)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Skoner, MD</name_or_title>
      <organization>Allegheny Singer Research Institute, WPAHS</organization>
      <phone>412-359-4099</phone>
      <email>dskoner@wpahs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

